Groombridge, Wu, Baughman & Stone LLP partner Dan Klein was quoted in Law360’s recent article, “Patent Cases To Watch In 2026,” which examines major patent disputes expected to shape the legal landscape in the coming year.
The article surveys a range of high-profile matters, including cases before the U.S. Supreme Court and the Federal Circuit involving generic drug “skinny labels,” USPTO authority, patent eligibility in biotechnology, and emerging issues tied to artificial intelligence and prior art.
Dan was quoted in connection with Hikma v. Amarin, a case in which the Supreme Court is considering whether to review a Federal Circuit decision addressing induced infringement and generic drug labeling. Commenting on the potential impact of the case, Dan noted that a Supreme Court reversal could narrow the range of post-launch conduct that creates infringement risk for generic drug manufacturers—an issue with significant implications for pharmaceutical patent disputes.